Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Affilogic, Takeda deal

    Affilogic Laboratories, Nantes, France Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology, Drug delivery Takeda and Affilogic partnered to validate and optimize therapies from Affilogics …

    Published on 9/26/2016
  • Akarna, Allergan deal

    Akarna Therapeutics Ltd., Cambridge, U.K. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Hepatic Allergan acquired Akarna for $50 million up front and undisclosed development, regulatory and sales milestones tied to…

    Published on 9/26/2016
  • Amgen, Dr. Reddys Laboratories Ltd. deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Dr. Reddys Laboratories Ltd. (NYSE:RDY), Hyderabad, India Business: Cancer, Musculoskeletal The companies added metastatic colorectal cancer (mCRC) drug Vectibix …

    Published on 9/26/2016
  • BioArctic, AbbVie deal

    BioArctic Neuroscience AB, Stockholm, Sweden AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Neurology BioArctic partnered with AbbVie to develop and commercialize BioArctics portfolio of antibodies against alpha …

    Published on 9/26/2016
  • biOasis, Vaccinex deal

    biOasis Technologies Inc. (TSX-V:BTI;OTCQB:BIOAF), Vancouver, B.C. Vaccinex Inc., Rochester, N.Y. Business: Autoimmune, Neurology, Drug delivery biOasis granted Vaccinex commercialization rights to use biOasis Transcend…

    Published on 9/26/2016
  • BioNTech, Genentech, Roche deal

    BioNTech AG, Mainz, Germany Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer Roches Genentech unit and BioNTech partnered to develop and commercialize …

    Published on 9/26/2016
  • CTI BioPharma, Shire deal

    CTI BioPharma Corp. (NASDAQ:CTIC;Milan:CTIC), Seattle, Wash. Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Hematology CTI said Shire terminated a 2013 license agreement and returned exclusive, worldwide …

    Published on 9/26/2016
  • Dermira, Maruho deal

    Dermira Inc. (NASDAQ:DERM), Menlo Park, Calif. Maruho Co. Ltd., Osaka, Japan Business: Other Dermira granted Maruho exclusive, Japanese rights to develop and commercialize DRM04. Dermira will receive $25 million up …

    Published on 9/26/2016
  • Evotec, Bayer deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Renal The companies partnered to develop candidates in kidney diseases, particularly chronic kidney disease (CKD). Under the …

    Published on 9/26/2016
  • Genenta Science, Amgen, Ospedale San Raffaele deal

    Genenta Science s.r.l., Milan, Italy Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Ospedale San Raffaele, Milan, Italy Business: Cancer Genenta, San Raffaele and Amgen partnered to evaluate myeloid-targeted …

    Published on 9/26/2016
  • Institut National de la Sante et de la Recherche Medicale, Evotec deal

    Institut National de la Sante et de la Recherche Medicale (INSERM), Paris, France Evotec AG (Xetra:EVT), Hamburg, Germany Business: Cancer Evotec partnered with INSERMs Inserm Transfert subsidiary to characterize and …

    Published on 9/26/2016
  • Madrigal, Tarveda Therapeutics deal

    Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL), West Conshohocken, Pa. Tarveda Therapeutics Inc., Watertown, Mass. Business: Cancer Madrigal granted Tarveda exclusive, worldwide rights to discover, develop and …

    Published on 9/26/2016
  • Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

    Max Delbrueck Center for Molecular Medicine Berlin-Buch, Berlin, Germany Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer The Max Delbrueck Center (MDC) granted Wilexs Heidelberg Pharma GmbH subsidiary an option …

    Published on 9/26/2016
  • NIH, Kite Pharma deal

    National Institutes of Health, Bethesda, Md. Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Business: Cancer NIH granted Kite an exclusive, worldwide license to undisclosed T cell receptor (TCR)-based products …

    Published on 9/26/2016
  • NuSirt Biopharma, OWL deal

    NuSirt Biopharma Inc., Nashville, Tenn. One Way Liver Genomics S.L., Derio, Spain Business: Diagnostic The companies partnered to develop diagnostic tools for trials of NuSirts Phase II candidate NS-0200 in non-…

    Published on 9/26/2016
  • Regeneron, Teva deal

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Neurology Teva and Regeneron partnered to develop and commercialize Regenerons…

    Published on 9/26/2016
  • Tobira, Allergan deal

    Tobira Therapeutics Inc. (NASDAQ:TBRA), San Francisco, Calif. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Hepatic Allergan will acquire Tobira for $28.35 per share in upfront cash plus a contingent value right (…

    Published on 9/26/2016
  • Viventia, Eleven Biotherapeutics deal

    Viventia Bio Inc., Mississauga, Ontario Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Business: Cancer Ophthalmic therapeutics company Eleven acquired cancer company Viventia. The combined company will …

    Published on 9/26/2016
  • Accurexa, DelMar Pharma deal

    Accurexa Inc. (OTCQX:ACXA), Newark, Del. DelMar Pharmaceuticals Inc. (OTCQX:DMPI), Vancouver, B.C. Business: Cancer, Drug delivery DelMar and Accurexa partnered to develop Accurexas ACX-31 implantable polymer wafer to …

    Published on 9/19/2016
  • AITbiotech, Novogene deal

    AITbiotech Pte. Ltd., Singapore Beijing Novogene Bioinformatics Technology Co. Ltd., Beijing, China Business: Supply/Service Beijing Novogene and AITbiotech formed JV NovogeneAIT Genomics Singapore to provide next-…

    Published on 9/19/2016
  • Basilea, Asahi Kasei Pharma deal

    Basilea Pharmaceutica Ltd. (SIX:BSLN), Basel, Switzerland Asahi Kasei Pharma Corp., Tokyo, Japan Business: Infectious Basilea granted Asahi exclusive rights in Japan to develop and commercialize isavuconazole. Basilea …

    Published on 9/19/2016
  • Basilea, Grupo Biotoscana deal

    Basilea Pharmaceutica Ltd. (SIX:BSLN), Basel, Switzerland Grupo Biotoscana S.L., Montevideo, Uruguay Business: Infectious Basilea granted Grupo Biotoscana exclusive rights to commercialize Cresemba isavuconazole and …

    Published on 9/19/2016
  • Circle Pharma, Pfizer deal

    Circle Pharma Inc., San Francisco, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Infectious Circle Pharma will build a screening library of permeable macrocycles designed to disrupt bioactive conformations …

    Published on 9/19/2016
  • Duchesnay, Alliance Pharma deal

    Duchesnay Inc., Blainville, Quebec Alliance Pharma plc (LSE:APH), Chippenham, U.K. Business: Gastrointestinal The partners added Germany, France, Italy and six additional undisclosed EU countries to a 2015 deal granting…

    Published on 9/19/2016
  • GlaxoSmithKline, Aspen deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Aspen Pharmacare Holdings Ltd. (JSE:APN), Durban, South Africa Business: Pharmaceuticals The partners terminated a 2009 deal to co-commercialize their product …

    Published on 9/19/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993